The biosimilars market is growing rapidly as healthcare systems seek more affordable alternatives to high-cost biologic medicines. The market was valued at USD 36.79 billion in 2024 and is projected to reach USD 282.3 billion by 2035, expanding at a CAGR of 20.35%. 1091 Biosimilars are highly similar versions of approved reference biologic medicines. They are developed through rigorous...